|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
11
|
|
pubmed:dateCreated |
2003-5-13
|
|
pubmed:abstractText |
The v-Abl protein encoded by Abelson murine leukemia virus (Ab-MLV) induces transformation of pre-B cells via a two-stage process. An initial proliferative phase during which cells with limited tumorigenic potential expand is followed by a crisis period marked by high levels of apoptosis and erratic growth. Transformants that survive this phase emerge as fully malignant cells and usually contain mutations that disable the p53 tumor suppressor pathway. Consistent with the importance of p53 in this process, pre-B cells from p53 null animals bypass crisis. Thus, the transformation process reflects a balance between signals from the v-Abl protein that drive transformation and those coming from the cellular response to inappropriate growth. One prediction of this hypothesis is that Ab-MLV mutants that are compromised in their ability to transform cells may be less equipped to overcome the effects of p53. To test this idea, we examined the ability of the P120/R273K mutant to transform pre-B cells from wild-type, p53 null, and Ink4a/Arf null mice. The SH2 domain of the v-Abl protein encoded by this mutant contains a substitution that affects the phosphotyrosine-binding pocket, and this mutant is compromised in its ability to transform NIH 3T3 and pre-B cells, especially at 39.5 degrees C. Our data reveal that loss of p53 or Ink4a/Arf locus products complements the transforming defect of the P120/R273K mutant, but it does not completely restore wild-type function. These results indicate that one important transforming function of v-Abl proteins is overcoming the effects of a functional p53 pathway.
|
|
pubmed:grant |
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/12743277-10373532,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12743277-10514006,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12743277-10543978,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12743277-10611241,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12743277-10775585,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12743277-10851051,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12743277-10860756,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12743277-11046134,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12743277-11160680,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12743277-11504915,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12743277-11584300,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12743277-11715018,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12743277-11781586,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12743277-12663768,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12743277-1370711,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12743277-1379715,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12743277-1525828,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12743277-1696637,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12743277-178822,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12743277-2005881,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12743277-2164639,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12743277-2852893,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12743277-3031469,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12743277-3035219,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12743277-6275106,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12743277-6304498,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12743277-7584069,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12743277-7807010,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12743277-7926759,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12743277-8164650,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12743277-8699021,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12743277-9119229,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12743277-9321394,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12743277-9694806,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12743277-9694807,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12743277-9789064
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
0022-538X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
77
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
6208-15
|
|
pubmed:dateRevised |
2009-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:12743277-3T3 Cells,
pubmed-meshheading:12743277-Abelson murine leukemia virus,
pubmed-meshheading:12743277-Animals,
pubmed-meshheading:12743277-Apoptosis,
pubmed-meshheading:12743277-B-Lymphocytes,
pubmed-meshheading:12743277-Cell Line,
pubmed-meshheading:12743277-Cell Line, Transformed,
pubmed-meshheading:12743277-Cell Transformation, Viral,
pubmed-meshheading:12743277-Humans,
pubmed-meshheading:12743277-Mice,
pubmed-meshheading:12743277-Mutation,
pubmed-meshheading:12743277-Oncogene Proteins v-abl,
pubmed-meshheading:12743277-Signal Transduction,
pubmed-meshheading:12743277-Temperature,
pubmed-meshheading:12743277-Tumor Suppressor Protein p53,
pubmed-meshheading:12743277-src Homology Domains
|
|
pubmed:year |
2003
|
|
pubmed:articleTitle |
Absence of p53 complements defects in Abelson murine leukemia virus signaling.
|
|
pubmed:affiliation |
Department of Pathology, Tufts University School of Medicine, Boston, Massachusetts 02111, USA.
|
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't
|
